Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with docetaxel as first-line treatment of women with metastatic breast cancer (MBC). In total, 41 patients with MBC were enrolled in a first-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciardiello, F, Troiani, T, Caputo, F, De Laurentiis, M, Tortora, G, Palmieri, G, De Vita, F, Diadema, M R, Orditura, M, Colantuoni, G, Gridelli, C, Catalano, G, De Placido, S, Bianco, A R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361320/
https://www.ncbi.nlm.nih.gov/pubmed/16685276
http://dx.doi.org/10.1038/sj.bjc.6603141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361320/
https://www.ncbi.nlm.nih.gov/pubmed/16685276
http://dx.doi.org/10.1038/sj.bjc.6603141

Ejemplares similares